Study type: Scientific review
DOI: 10.1186/s43088-026-00844-w
Related subjects
- Alpinia galanga
Introduction
A critical narrative review published 21 October 2026 by researchers in Malaysia, Australia and Taiwan examined how ginger varieties, cultivation, processing, extracts and bioavailability affect reported antimicrobial results. The review describes plausible laboratory signals but insufficient standardized, human clinical evidence to use ginger as a proven substitute for anti-infective medicines.
On this page
Research card: location and authors
Countries of the author institutions: Malaysia, Australia and Taiwan. The contributors are affiliated with Sunway University and Sunway College in Sunway City, Malaysia; University of Technology Sydney and Charles Sturt University in Australia; and Taipei Medical University in Taiwan. Unlike a clinical or field experiment, this work was a collaborative analysis of published literature, not a new experiment at a single laboratory or hospital. Type: peer-reviewed critical narrative review; published: 21 October 2026 in Beni-Suef University Journal of Basic and Applied Sciences, DOI 10.1186/s43088-026-00844-w. [1]
What question did the authors investigate?
Why do Zingiber officinale extracts repeatedly show antibacterial, antifungal or other antimicrobial signals in laboratories, while a reliable clinical treatment has not emerged? The review connects botanical identification, cultivars, growth conditions, maturity, drying, heating, extraction, chemical composition, microbiological assays, human exposure and delivery systems. The closely related Alpinia galanga is a distinct plant in the Zingiberaceae family; it was not the subject of this ginger review, and ginger evidence must not be transferred to it.
What evidence was reviewed?
The authors describe literature identification through PubMed/MEDLINE, Scopus, Web of Science, ScienceDirect and Google Scholar, prioritizing interpretable descriptions of authentic ginger preparations. The reviewed materials include fresh and dried rhizomes, powder, essential oils, oleoresins, aqueous/solvent extracts, standardized fractions and isolated gingerols or shogaols. Methods considered include inhibition zones, MIC, antibiofilm assays, mechanistic tests, pharmacokinetics and limited human trials. This is not a registered systematic review or meta-analysis, and there is no new patient sample or pooled treatment effect. [1]
Why ginger materials are not interchangeable
The same common name can mask major differences in genotype, soil, geography, harvest maturity, drying temperature, storage and solvent. Heating and drying can shift the balance of gingerols and shogaols, while oils emphasize volatile compounds. A reported minimum inhibitory concentration for a solvent extract cannot be converted into a household serving of ginger tea or food. Different microbial strains and experimental conditions also make inhibition-zone results and broth-MIC measurements hard to compare.
What do laboratory findings actually establish?
Experiments have reported inhibition of microbial growth, interference with membranes, biofilms, quorum sensing or enzymes for various ginger-derived materials. However, isolated antioxidant readings, computational molecular docking or a single growth-inhibition zone do not prove an antimicrobial mechanism or a useful human treatment. The review calls for botanical authentication, validated HPTLC, HPLC/UPLC, LC-MS/MS or GC-MS characterization, appropriate solvent/drug comparators, dose-response testing and reproducibility. [1]
Can active concentrations reach human infection sites?
The review emphasizes that gingerols and shogaols undergo extensive metabolism, including reduction, glucuronidation, sulfation and conjugation. The nominal extract dose and the free compound concentration in a laboratory dish therefore cannot be assumed to equal the concentration at a human infection site. Standardized formulations and nanodelivery concepts are experimental possibilities, but require independent safety and exposure testing.
Strength, limitations and common claim
Strength: a broad, peer-reviewed synthesis exposing gaps between botanical chemistry, assays and practical treatment. Limitations: critical narrative selection, heterogeneous preparations and protocols, limited comparison of negative results, no pooled clinical effect and few adequately controlled human infection-treatment trials. Claim: “Ginger is a proven natural antibiotic.” Verdict: unsupported. Laboratory antimicrobial promise is not demonstrated clinical treatment. [1]
Safety and practical meaning
Culinary ginger is not chemically equivalent to a concentrated essential oil, extract or supplement. The review does not provide an antibacterial dose for patients and does not justify substituting ginger for prescribed antibiotics, antifungals or antivirals. More reliable studies must specify the actual product and use reproducible assays, pharmacokinetics, toxicity and clinical outcomes.
Funding, conflicts and conclusion
The paper reports no funding, no new experimental data and no declared competing interests. It concludes that ginger may provide candidates for standardized future products, but should not be promoted as a clinically validated anti-infective replacement without high-quality human evidence. [1]
Important note
This is a narrative review, not a new clinical trial or proof of ginger treating human infections. Fresh ginger food, essential oil and concentrated extracts are not interchangeable, nor can MIC values be translated into household doses. Do not replace prescribed antibacterial, antifungal or antiviral therapy with ginger on the basis of in-vitro findings.
This article provides educational information and does not replace advice from a qualified healthcare professional.
Sources and references
- From cultivation to clinical translation: a critical review of ginger phytochemistry, antimicrobial mechanisms, bioavailability, and standardization · Read source — Beni-Suef University Journal of Basic and Applied Sciences